Literature DB >> 15921851

Biological effects of TrkA and TrkB receptor signaling in neuroblastoma.

Alexander Schramm1, Johannes H Schulte, Kathy Astrahantseff, Ognjan Apostolov, Vera van Limpt, Hauke Sieverts, Steffi Kuhfittig-Kulle, Petra Pfeiffer, Rogier Versteeg, Angelika Eggert.   

Abstract

The Trk family consists of three receptor tyrosine kinases, each of which can be activated by one or more of four neurotrophins-NGF, BDNF, NT3 and NT4. Neurotrophins mediate their multiple effects through a number of distinct intracellular signaling cascades regulating such diverse biological responses as cell survival, proliferation and differentiation in normal and neoplastic neuronal cells. Expression of Trk receptors also plays an important role in the biology and clinical behavior of neuroblastomas. High expression of TrkA is present in neuroblastomas with favorable biological features and highly correlated with patient survival, whereas TrkB is mainly expressed on unfavorable, aggressive neuroblastomas. This short review discusses recent data on the biological roles of TrkA and TrkB signaling in neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15921851     DOI: 10.1016/j.canlet.2005.02.051

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  34 in total

1.  Therapeutic efficacy of silibinin on human neuroblastoma cells: Akt and NF-κB expressions may play an important role in silibinin-induced response.

Authors:  Meysam Yousefi; Seyed H Ghaffari; Bahram M Soltani; Shahriar Nafissi; Majid Momeny; Ali Zekri; Mehrdad Behmanesh; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Neurochem Res       Date:  2012-06-21       Impact factor: 3.996

2.  Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis.

Authors:  Petra Obexer; Judith Hagenbuchner; Thomas Unterkircher; Nora Sachsenmaier; Christoph Seifarth; Günther Böck; Verena Porto; Kathrin Geiger; Michael Ausserlechner
Journal:  Mol Biol Cell       Date:  2009-02-11       Impact factor: 4.138

3.  Cellular assays for high-throughput screening for modulators of Trk receptor tyrosine kinases.

Authors:  Jun Wang; Michael K Hancock; Jeanne M Dudek; Kun Bi
Journal:  Curr Chem Genomics       Date:  2008-02-25

4.  TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells.

Authors:  Siyang Zhang; Dawei Guo; Wenting Luo; Qingfu Zhang; Ying Zhang; Chunyan Li; Yao Lu; Zeshi Cui; Xueshan Qiu
Journal:  BMC Cancer       Date:  2010-02-16       Impact factor: 4.430

5.  Differentiation in neuroblastoma: diffusion-limited hypoxia induces neuro-endocrine secretory protein 55 and other markers of a chromaffin phenotype.

Authors:  Fredrik Hedborg; Reiner Fischer-Colbrie; Nurtena Ostlin; Bengt Sandstedt; Maxine G B Tran; Patrick H Maxwell
Journal:  PLoS One       Date:  2010-09-17       Impact factor: 3.240

6.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.

Authors:  David T W Jones; Barbara Hutter; Natalie Jäger; Andrey Korshunov; Marcel Kool; Hans-Jörg Warnatz; Thomas Zichner; Sally R Lambert; Marina Ryzhova; Dong Anh Khuong Quang; Adam M Fontebasso; Adrian M Stütz; Sonja Hutter; Marc Zuckermann; Dominik Sturm; Jan Gronych; Bärbel Lasitschka; Sabine Schmidt; Huriye Seker-Cin; Hendrik Witt; Marc Sultan; Meryem Ralser; Paul A Northcott; Volker Hovestadt; Sebastian Bender; Elke Pfaff; Sebastian Stark; Damien Faury; Jeremy Schwartzentruber; Jacek Majewski; Ursula D Weber; Marc Zapatka; Benjamin Raeder; Matthias Schlesner; Catherine L Worth; Cynthia C Bartholomae; Christof von Kalle; Charles D Imbusch; Sylwester Radomski; Chris Lawerenz; Peter van Sluis; Jan Koster; Richard Volckmann; Rogier Versteeg; Hans Lehrach; Camelia Monoranu; Beate Winkler; Andreas Unterberg; Christel Herold-Mende; Till Milde; Andreas E Kulozik; Martin Ebinger; Martin U Schuhmann; Yoon-Jae Cho; Scott L Pomeroy; Andreas von Deimling; Olaf Witt; Michael D Taylor; Stephan Wolf; Matthias A Karajannis; Charles G Eberhart; Wolfram Scheurlen; Martin Hasselblatt; Keith L Ligon; Mark W Kieran; Jan O Korbel; Marie-Laure Yaspo; Benedikt Brors; Jörg Felsberg; Guido Reifenberger; V Peter Collins; Nada Jabado; Roland Eils; Peter Lichter; Stefan M Pfister
Journal:  Nat Genet       Date:  2013-06-30       Impact factor: 38.330

7.  Comparison of tyrosine kinase domain properties for the neurotrophin receptors TrkA and TrkB.

Authors:  Stephen C Artim; Anatoly Kiyatkin; Mark A Lemmon
Journal:  Biochem J       Date:  2020-10-30       Impact factor: 3.857

8.  ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome.

Authors:  Sidong Huang; Jamila Laoukili; Mirjam T Epping; Jan Koster; Michael Hölzel; Bart A Westerman; Wouter Nijkamp; Akiko Hata; Shahab Asgharzadeh; Robert C Seeger; Rogier Versteeg; Roderick L Beijersbergen; René Bernards
Journal:  Cancer Cell       Date:  2009-04-07       Impact factor: 31.743

9.  Characterization of critical domains within the tumor suppressor CASZ1 required for transcriptional regulation and growth suppression.

Authors:  Ryan A Virden; Carol J Thiele; Zhihui Liu
Journal:  Mol Cell Biol       Date:  2012-02-13       Impact factor: 4.272

10.  c.1810C>T polymorphism of NTRK1 gene is associated with reduced survival in neuroblastoma patients.

Authors:  Beata S Lipska; Elzbieta Drozynska; Paola Scaruffi; Gian Paolo Tonini; Ewa Izycka-Swieszewska; Szymon Zietkiewicz; Anna Balcerska; Danuta Perek; Alicja Chybicka; Wojciech Biernat; Janusz Limon
Journal:  BMC Cancer       Date:  2009-12-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.